Treatment-related death in patients with small-cell lung cancer in phase III trials over the last two decades

Nobuaki Ochi, Katsuyuki Hotta, Nagio Takigawa, Isao Oze, Yoshiro Fujiwara, Eiki Ichihara, Akiko Hisamoto, Masahiro Tabata, Mitsune Tanimoto, Katsuyuki Kiura

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Introduction: Treatment-related death (TRD) remains a serious problem in small-cell lung cancer (SCLC), despite recent improvements in supportive care. However, few studies have formally assessed time trends in the proportion of TRD over the past two decades. The aim of this study was to determine the frequency and pattern of TRD over time. Methods: We examined phase 3 trials conducted between 1990 and 2010 to address the role of systemic treatment for SCLC. The time trend was assessed using linear regression analysis. Results: In total, 97 trials including nearly 25,000 enrolled patients were analyzed. The overall TRD proportion was 2.95%. Regarding the time trend, while it was not statistically significant, it tended to decrease, with a 0.138% decrease per year and 2.76% decrease per two decades. The most common cause of death was febrile neutropenia without any significant time trend in its incidence over the years examined (p = 0.139). However, deaths due to febrile neutropenia as well as all causes in patients treated with non-platinum chemotherapy increased significantly (p = 0.033). Conclusions: The overall TRD rate has been low, but not negligible, in phase III trials for SCLC over the past two decades.

Original languageEnglish
Article numbere42798
JournalPLoS One
Volume7
Issue number8
DOIs
Publication statusPublished - Aug 6 2012

Fingerprint

Chemotherapy
Small Cell Lung Carcinoma
lung neoplasms
Linear regression
Regression analysis
Cells
death
Febrile Neutropenia
neutropenia
cells
fever
Therapeutics
drug therapy
Cause of Death
Linear Models
regression analysis
Regression Analysis
Drug Therapy
incidence
Mortality

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Treatment-related death in patients with small-cell lung cancer in phase III trials over the last two decades. / Ochi, Nobuaki; Hotta, Katsuyuki; Takigawa, Nagio; Oze, Isao; Fujiwara, Yoshiro; Ichihara, Eiki; Hisamoto, Akiko; Tabata, Masahiro; Tanimoto, Mitsune; Kiura, Katsuyuki.

In: PLoS One, Vol. 7, No. 8, e42798, 06.08.2012.

Research output: Contribution to journalArticle

Ochi, Nobuaki ; Hotta, Katsuyuki ; Takigawa, Nagio ; Oze, Isao ; Fujiwara, Yoshiro ; Ichihara, Eiki ; Hisamoto, Akiko ; Tabata, Masahiro ; Tanimoto, Mitsune ; Kiura, Katsuyuki. / Treatment-related death in patients with small-cell lung cancer in phase III trials over the last two decades. In: PLoS One. 2012 ; Vol. 7, No. 8.
@article{b8bef39a33764dd59800c8f52b951f21,
title = "Treatment-related death in patients with small-cell lung cancer in phase III trials over the last two decades",
abstract = "Introduction: Treatment-related death (TRD) remains a serious problem in small-cell lung cancer (SCLC), despite recent improvements in supportive care. However, few studies have formally assessed time trends in the proportion of TRD over the past two decades. The aim of this study was to determine the frequency and pattern of TRD over time. Methods: We examined phase 3 trials conducted between 1990 and 2010 to address the role of systemic treatment for SCLC. The time trend was assessed using linear regression analysis. Results: In total, 97 trials including nearly 25,000 enrolled patients were analyzed. The overall TRD proportion was 2.95{\%}. Regarding the time trend, while it was not statistically significant, it tended to decrease, with a 0.138{\%} decrease per year and 2.76{\%} decrease per two decades. The most common cause of death was febrile neutropenia without any significant time trend in its incidence over the years examined (p = 0.139). However, deaths due to febrile neutropenia as well as all causes in patients treated with non-platinum chemotherapy increased significantly (p = 0.033). Conclusions: The overall TRD rate has been low, but not negligible, in phase III trials for SCLC over the past two decades.",
author = "Nobuaki Ochi and Katsuyuki Hotta and Nagio Takigawa and Isao Oze and Yoshiro Fujiwara and Eiki Ichihara and Akiko Hisamoto and Masahiro Tabata and Mitsune Tanimoto and Katsuyuki Kiura",
year = "2012",
month = "8",
day = "6",
doi = "10.1371/journal.pone.0042798",
language = "English",
volume = "7",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "8",

}

TY - JOUR

T1 - Treatment-related death in patients with small-cell lung cancer in phase III trials over the last two decades

AU - Ochi, Nobuaki

AU - Hotta, Katsuyuki

AU - Takigawa, Nagio

AU - Oze, Isao

AU - Fujiwara, Yoshiro

AU - Ichihara, Eiki

AU - Hisamoto, Akiko

AU - Tabata, Masahiro

AU - Tanimoto, Mitsune

AU - Kiura, Katsuyuki

PY - 2012/8/6

Y1 - 2012/8/6

N2 - Introduction: Treatment-related death (TRD) remains a serious problem in small-cell lung cancer (SCLC), despite recent improvements in supportive care. However, few studies have formally assessed time trends in the proportion of TRD over the past two decades. The aim of this study was to determine the frequency and pattern of TRD over time. Methods: We examined phase 3 trials conducted between 1990 and 2010 to address the role of systemic treatment for SCLC. The time trend was assessed using linear regression analysis. Results: In total, 97 trials including nearly 25,000 enrolled patients were analyzed. The overall TRD proportion was 2.95%. Regarding the time trend, while it was not statistically significant, it tended to decrease, with a 0.138% decrease per year and 2.76% decrease per two decades. The most common cause of death was febrile neutropenia without any significant time trend in its incidence over the years examined (p = 0.139). However, deaths due to febrile neutropenia as well as all causes in patients treated with non-platinum chemotherapy increased significantly (p = 0.033). Conclusions: The overall TRD rate has been low, but not negligible, in phase III trials for SCLC over the past two decades.

AB - Introduction: Treatment-related death (TRD) remains a serious problem in small-cell lung cancer (SCLC), despite recent improvements in supportive care. However, few studies have formally assessed time trends in the proportion of TRD over the past two decades. The aim of this study was to determine the frequency and pattern of TRD over time. Methods: We examined phase 3 trials conducted between 1990 and 2010 to address the role of systemic treatment for SCLC. The time trend was assessed using linear regression analysis. Results: In total, 97 trials including nearly 25,000 enrolled patients were analyzed. The overall TRD proportion was 2.95%. Regarding the time trend, while it was not statistically significant, it tended to decrease, with a 0.138% decrease per year and 2.76% decrease per two decades. The most common cause of death was febrile neutropenia without any significant time trend in its incidence over the years examined (p = 0.139). However, deaths due to febrile neutropenia as well as all causes in patients treated with non-platinum chemotherapy increased significantly (p = 0.033). Conclusions: The overall TRD rate has been low, but not negligible, in phase III trials for SCLC over the past two decades.

UR - http://www.scopus.com/inward/record.url?scp=84864717387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864717387&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0042798

DO - 10.1371/journal.pone.0042798

M3 - Article

C2 - 22880112

AN - SCOPUS:84864717387

VL - 7

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 8

M1 - e42798

ER -